| Patrick Coady, MD | |
|
40 Temple St, 3rd Floor, New Haven, CT 06510-2715 | |
| (203) 785-2020 | |
| Not Available |
| Full Name | Patrick Coady |
|---|---|
| Gender | Male |
| Speciality | Ophthalmology |
| Experience | 15 Years |
| Location | 40 Temple St, New Haven, Connecticut |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1760736755 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207W00000X | Ophthalmology | 53016 (Connecticut) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Saint Clare's Hospital/ Denville Campus | Denville, NJ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Monmouth Retina Consultants Pa | 2860492170 | 12 |
| Daniel Y Kim Md Pa | 8628047545 | 5 |
| Monmouth Retina Consultants Pa | 2860492170 | 12 |
News Archive
The Campaign to Stop Colon Cancer Now, a campaign to increase screenings and prevent the nation's second-leading cancer killer, launched today in conjunction with National Colorectal Cancer Awareness Month in March.
Lux Biosciences, Inc. today announced its submission of simultaneous regulatory filings to both the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) seeking marketing approval for its investigational drug LUVENIQ™ (LX211; oral voclosporin) for the treatment of noninfectious uveitis involving the intermediate or posterior segments of the eye.
The global CT market is expected to grow 5.5 percent to $5.1 billion in 2018, according to a new Kalorama Information report. The combination of product enhancements and the need to cut radiation dose levels is fueling the market. A new federal standard passed into law last year, NEMA Standard XR-29, defining low dose standards and punishing providers not in compliance will help growth, according to the market research publisher.
Biothera researchers have broadened their understanding of a biomarker that may enable doctors to predict which cancer patients will best respond to Imprime PGG®, the company's immunotherapy in Phase 3 drug development for colorectal cancer.
Urban Health Plan in the South Bronx is revolutionizing the way patients are identified and tracked at their network of community health centers. From identifying patients through an iris recognition scan to managing their patients' health through a fully electronic system, UHP is able to provide state-of-the-art, quality and comprehensive care to thousands of New York's neediest residents. This week, their efforts were recognized by the Healthcare Information and Management Systems Society who awarded them the 2009 HIMSS Davies Award of Excellence. Urban Health Plan uses eClinicalWorks (ECW) as its electronic health record (EHR) system.
› Verified 9 days ago
| Entity Name | Daniel Y Kim Md Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1073582805 PECOS PAC ID: 8628047545 Enrollment ID: O20040928000749 |
News Archive
The Campaign to Stop Colon Cancer Now, a campaign to increase screenings and prevent the nation's second-leading cancer killer, launched today in conjunction with National Colorectal Cancer Awareness Month in March.
Lux Biosciences, Inc. today announced its submission of simultaneous regulatory filings to both the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) seeking marketing approval for its investigational drug LUVENIQ™ (LX211; oral voclosporin) for the treatment of noninfectious uveitis involving the intermediate or posterior segments of the eye.
The global CT market is expected to grow 5.5 percent to $5.1 billion in 2018, according to a new Kalorama Information report. The combination of product enhancements and the need to cut radiation dose levels is fueling the market. A new federal standard passed into law last year, NEMA Standard XR-29, defining low dose standards and punishing providers not in compliance will help growth, according to the market research publisher.
Biothera researchers have broadened their understanding of a biomarker that may enable doctors to predict which cancer patients will best respond to Imprime PGG®, the company's immunotherapy in Phase 3 drug development for colorectal cancer.
Urban Health Plan in the South Bronx is revolutionizing the way patients are identified and tracked at their network of community health centers. From identifying patients through an iris recognition scan to managing their patients' health through a fully electronic system, UHP is able to provide state-of-the-art, quality and comprehensive care to thousands of New York's neediest residents. This week, their efforts were recognized by the Healthcare Information and Management Systems Society who awarded them the 2009 HIMSS Davies Award of Excellence. Urban Health Plan uses eClinicalWorks (ECW) as its electronic health record (EHR) system.
› Verified 9 days ago
| Entity Name | Monmouth Retina Consultants Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1437179942 PECOS PAC ID: 2860492170 Enrollment ID: O20070111000161 |
News Archive
The Campaign to Stop Colon Cancer Now, a campaign to increase screenings and prevent the nation's second-leading cancer killer, launched today in conjunction with National Colorectal Cancer Awareness Month in March.
Lux Biosciences, Inc. today announced its submission of simultaneous regulatory filings to both the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) seeking marketing approval for its investigational drug LUVENIQ™ (LX211; oral voclosporin) for the treatment of noninfectious uveitis involving the intermediate or posterior segments of the eye.
The global CT market is expected to grow 5.5 percent to $5.1 billion in 2018, according to a new Kalorama Information report. The combination of product enhancements and the need to cut radiation dose levels is fueling the market. A new federal standard passed into law last year, NEMA Standard XR-29, defining low dose standards and punishing providers not in compliance will help growth, according to the market research publisher.
Biothera researchers have broadened their understanding of a biomarker that may enable doctors to predict which cancer patients will best respond to Imprime PGG®, the company's immunotherapy in Phase 3 drug development for colorectal cancer.
Urban Health Plan in the South Bronx is revolutionizing the way patients are identified and tracked at their network of community health centers. From identifying patients through an iris recognition scan to managing their patients' health through a fully electronic system, UHP is able to provide state-of-the-art, quality and comprehensive care to thousands of New York's neediest residents. This week, their efforts were recognized by the Healthcare Information and Management Systems Society who awarded them the 2009 HIMSS Davies Award of Excellence. Urban Health Plan uses eClinicalWorks (ECW) as its electronic health record (EHR) system.
› Verified 9 days ago
| Entity Name | Vitreous Retina Macula Specialists Of Nj |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1760788996 PECOS PAC ID: 0547447153 Enrollment ID: O20110608000462 |
News Archive
The Campaign to Stop Colon Cancer Now, a campaign to increase screenings and prevent the nation's second-leading cancer killer, launched today in conjunction with National Colorectal Cancer Awareness Month in March.
Lux Biosciences, Inc. today announced its submission of simultaneous regulatory filings to both the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) seeking marketing approval for its investigational drug LUVENIQ™ (LX211; oral voclosporin) for the treatment of noninfectious uveitis involving the intermediate or posterior segments of the eye.
The global CT market is expected to grow 5.5 percent to $5.1 billion in 2018, according to a new Kalorama Information report. The combination of product enhancements and the need to cut radiation dose levels is fueling the market. A new federal standard passed into law last year, NEMA Standard XR-29, defining low dose standards and punishing providers not in compliance will help growth, according to the market research publisher.
Biothera researchers have broadened their understanding of a biomarker that may enable doctors to predict which cancer patients will best respond to Imprime PGG®, the company's immunotherapy in Phase 3 drug development for colorectal cancer.
Urban Health Plan in the South Bronx is revolutionizing the way patients are identified and tracked at their network of community health centers. From identifying patients through an iris recognition scan to managing their patients' health through a fully electronic system, UHP is able to provide state-of-the-art, quality and comprehensive care to thousands of New York's neediest residents. This week, their efforts were recognized by the Healthcare Information and Management Systems Society who awarded them the 2009 HIMSS Davies Award of Excellence. Urban Health Plan uses eClinicalWorks (ECW) as its electronic health record (EHR) system.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Patrick Coady, MD 2195 Sacramento St, Apt. 302, San Francisco, CA 94109-3356 Ph: () - | Patrick Coady, MD 40 Temple St, 3rd Floor, New Haven, CT 06510-2715 Ph: (203) 785-2020 |
News Archive
The Campaign to Stop Colon Cancer Now, a campaign to increase screenings and prevent the nation's second-leading cancer killer, launched today in conjunction with National Colorectal Cancer Awareness Month in March.
Lux Biosciences, Inc. today announced its submission of simultaneous regulatory filings to both the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) seeking marketing approval for its investigational drug LUVENIQ™ (LX211; oral voclosporin) for the treatment of noninfectious uveitis involving the intermediate or posterior segments of the eye.
The global CT market is expected to grow 5.5 percent to $5.1 billion in 2018, according to a new Kalorama Information report. The combination of product enhancements and the need to cut radiation dose levels is fueling the market. A new federal standard passed into law last year, NEMA Standard XR-29, defining low dose standards and punishing providers not in compliance will help growth, according to the market research publisher.
Biothera researchers have broadened their understanding of a biomarker that may enable doctors to predict which cancer patients will best respond to Imprime PGG®, the company's immunotherapy in Phase 3 drug development for colorectal cancer.
Urban Health Plan in the South Bronx is revolutionizing the way patients are identified and tracked at their network of community health centers. From identifying patients through an iris recognition scan to managing their patients' health through a fully electronic system, UHP is able to provide state-of-the-art, quality and comprehensive care to thousands of New York's neediest residents. This week, their efforts were recognized by the Healthcare Information and Management Systems Society who awarded them the 2009 HIMSS Davies Award of Excellence. Urban Health Plan uses eClinicalWorks (ECW) as its electronic health record (EHR) system.
› Verified 9 days ago
Dr. Michael Ehrlich, M.D. Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 40 Temple Street, Yale Ophthalmology, New Haven, CT 06510 Phone: 203-395-7949 Fax: 203-785-7090 | |
Dr. Susan Hall Forster, MD Ophthalmology Medicare: Medicare Enrolled Practice Location: 55 Lock Street, New Haven, CT 06520 Phone: 203-432-0076 Fax: 203-432-7289 | |
Dr. Wayne Ian Larrison, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 46 Prince St, Suite 402a, New Haven, CT 06519 Phone: 203-787-6161 Fax: 203-776-0300 | |
Philip Carl Palmisano, MD Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 800 Howard Ave, Yale Physicians Building, New Haven, CT 06519 Phone: 203-785-2140 Fax: 203-785-6414 | |
Dr. Ji Liu, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 40 Temple St, Suite 1b, New Haven, CT 06510 Phone: 203-785-3360 Fax: 203-785-7090 | |
Dr. Aryan Shayegani, MD Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 40 Temple St, Suite 3-a, New Haven, CT 06510 Phone: 203-785-2020 Fax: 203-785-6123 | |
Dr. David Silverstone, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 40 Temple St, Suite 5b, New Haven, CT 06510 Phone: 203-789-2020 Fax: 203-562-6028 |